New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 25, 2013
10:01 EDTWAGE, TEVA, TIVO, TWX, VIAB, VET, LCI, SUBCY, SAPMY, STRZA, NFLX, NGL, KYTH, MYL, HASI, ACT, DISH, DISCA, DTV, DIS, FOXAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 21st Century Fox (FOXA) initiated with an Outperform at FBR Capital... Actavis (ACT) initiated with a Buy at Citigroup.... DISH (DISH) initiated with an Underperform at FBR Capital... DirecTV (DTV) initiated with a Market Perform at FBR Capital... Discovery (DISCA) initiated with an Outperform at FBR Capital... Disney (DIS) initiated with an Outperform at FBR Capital... Hannon Armstrong (HASI) initiated with a Sector Perform at RBC Capital... Kythera (KYTH) initiated with a Buy at BofA/Merrill... Mylan (MYL) initiated with a Neutral at Citigroup... NGL Energy Partners (NGL) initiated with an Outperform at Raymond James... Netflix (NFLX) initiated with a Market Perform at FBR Capital... Starz (STRZA) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with a Buy at Citigroup... TiVo (TIVO) initiated with a Market Perform at FBR Capital... Time Warner (TWX) initiated with an Outperform at FBR Capital... Vermilion Energy (VET) initiated with a Neutral at Goldman... Viacom (VIAB) initiated with an Outperform at FBR Capital... Lannett (LCI) initiated with a Buy at BofA/Merrill... Subsea 7 (SUBCY) initiated with a Buy at Canaccord... Saipem (SAPMY) initiated with a Hold at Canaccord... WageWorks (WAGE) initiated with a Buy at SunTrust.
News For FOXA;ACT;DISH;DISCA;DTV;DIS;HASI;MYL;KYTH;NGL;NFLX;STRZA;TEVA;TIVO;TWX;VIAB;VET;LCI;SUBCY;SAPMY;WAGE From The Last 14 Days
Check below for free stories on FOXA;ACT;DISH;DISCA;DTV;DIS;HASI;MYL;KYTH;NGL;NFLX;STRZA;TEVA;TIVO;TWX;VIAB;VET;LCI;SUBCY;SAPMY;WAGE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
September 3, 2014
13:38 EDTNFLXNetflix acquires rights to 'Gotham' series for $1.75M per episode, Deadline says
Netflix has acquired the streaming rights for the upcoming drama series "Gotham" for $1.75M per episode, Deadline reports. This exclusive streaming rights purchase is the first deal to be made for a broadcast series before its television premiere, Deadline added. Reference Link
10:47 EDTDISHOpco sees DISH trying to buy T-Mobile for $40/share
Oppenheimer earlier today said it sees DISH (DISH) trying to acquire T-Mobile (TMUS) for $40 per share, and that there is a 20% chance a deal could be announced ahead of the September 10 FCC-mandated quiet period. Opco does not believe DISH can successfully partner with Sprint (S) or T-Moblile (TMUS), leaving buying T-Mobile or selling spectrum as its primary options. The firm expects additional wireless consolidation within the next year, and lists the most likely outcomes as a T-Mobile/DISH merger or T-Mobile/Comcast (CMCSA) merger.
10:35 EDTDISHDISH may try to acquire T-Mobile for $40/share, says Oppenheimer
Oppenheimer says it believes DISH (DISH) could try to acquire T-Mobile (TMUS) for $40 per share. The firm sees a 20% chance of a deal being announced ahead of the FCC-mandated quiet period on September 10.
10:07 EDTNFLXNetflix volatility low as shares at record high
Subscribe for More Information
09:36 EDTNFLXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TSLA TWTR PBR C GILD NFLX FB BIDU
07:18 EDTTWXTime Warner pursues Sony exec for Turner post, NY Post says
Time Warner's (TWX) Turner Broadcasting is pursuing Sony Pictures TV (SNE) executive Zack Van Amburg to become the unit's new entertainment chief after the departure of Steve Koonin, said the New York Post, citing sources. Reference Link
06:56 EDTTWXWarner Bros. aiming for worker buyouts to up profit, Bloomberg says
Subscribe for More Information
06:03 EDTDIS, DISHDISH plans to call upcoming internet TV service Nutv, GigaOM reports
Subscribe for More Information
05:44 EDTTEVATeva announces positive judgement in patent case against AstraZeneca
Subscribe for More Information
05:29 EDTTWX, NFLXNetflix announces Gotham to be released exclusively on Netflix
Subscribe for More Information
September 2, 2014
19:59 EDTTWXTime Warner said to plan buyout offers to boost profit, Bloomberg reports
Subscribe for More Information
16:30 EDTKYTHKythera files $200M mixed securities shelf
16:00 EDTNFLXOptions Update; September 2, 2014
Subscribe for More Information
09:41 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:23 EDTACTActavis announced FDA accepted filing of eluxadoline's NDA
Subscribe for More Information
08:07 EDTWAGEWageWorks names Colm Callan as CFO, effective immediately
Subscribe for More Information
08:02 EDTTEVATeva reports statistically significant results in reslizumab trial
Teva Pharmaceutical Industries announced that reslizumab, an investigational anti-IL-5 monoclonal antibody, demonstrated clear levels of efficacy in achieving the primary endpoint of reduction in the frequency of clinical asthma exacerbations compared to placebo in two pivotal Phase III studies in patients with inadequately controlled moderate to severe asthma with elevated levels of blood eosinophils. In both trials, reslizumab treatment showed both clinically relevant and statistically significant reductions in the frequency of CAE compared to placebo. Reslizumab has also demonstrated a positive effect on lung function and asthma control in the Phase III program . The combination of an effect on clinically important exacerbations and on improvements and preservation of lung function suggest that reslizumab may be a uniquely differentiated treatment for patients with moderate to severe asthma with elevated levels of blood eosinophils. This initial set of results shows the adverse event profile of reslizumab was comparable to placebo in both trials. The incidence of common AEs was consistent with those seen in a moderate to severe asthma population, the most frequent being upper respiratory tract infections, asthma and headache. Further analyses of additional efficacy and safety data are ongoing. These new data are from two global Phase III 12-month, randomized, double-blind, placebo-controlled, parallel-group studies, evaluating the efficacy and safety of intravenously administered reslizumab once every four weeks, compared to placebo in asthma patients that are inadequately controlled by standard of care therapy.
07:47 EDTFOXA21st Century Fox risk/reward positive, says Bernstein
Bernstein believes that 21st Century Fox's stock can climb 30% if the company meets its EBITDA target of $8.1B. If the company misses the target by $300M, the stock may only drop 3%, estimated the firm, which keeps a $46 price target and Outperform rating on the shares.
07:36 EDTVIAB, DISDisney wins another weekend with 'Guardians,' LA Times reports
Subscribe for More Information
06:34 EDTDIS, TWXA+E Networks could buy 10% of Vice Media for $250M, WSJ reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use